- Q1 2024 Cardiff Oncology Inc Earnings Call TranscriptMay 02, 2024€3.9 (-3.35%)Earnings
- Q4 2023 Cardiff Oncology Inc Earnings Call TranscriptFeb 29, 2024€1.64 (+2.24%)Earnings
- Q3 2023 Cardiff Oncology Inc Earnings Call TranscriptNov 02, 2023€0.994 (+2.05%)Earnings
- Cardiff Oncology Inc Clinical Update Call TranscriptSep 26, 2023
- Cardiff Oncology Inc Clinical and Corporate Update Call TranscriptAug 07, 2023
- Cardiff Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Cardiff Oncology Inc at Cowen Health Care Conference- GI/GU Oncology Panel TranscriptMar 07, 2023
- Cardiff Oncology Inc at JMP Securities Hematology Oncology Summit (Virtual) TranscriptDec 07, 2022
- Cardiff Oncology Inc at Piper Sandler Healthcare Conference TranscriptNov 29, 2022
- Cardiff Oncology Inc to Provide a Clinical and Corporate Update Call TranscriptSep 12, 2022
- Cardiff Oncology Inc to Discuss Updated Data from Lead Clinical Program in KRAS-mutated Metastatic Colorectal Cancer at ASCO-GI TranscriptJan 18, 2022
- Cardiff Oncology Inc to Discuss New Data from Lead Clinical Program in KRAS-mutated mCRC Webinar TranscriptSep 08, 2021
- Cardiff Oncology Inc at William Blair Biotech Focus Conference (Virtual) TranscriptJul 15, 2021
- Cardiff Oncology Inc KOL Webinar TranscriptApr 12, 2021
- Cardiff Oncology Inc Discusses KRAS Mutations in Cancer TranscriptOct 14, 2020
- Cardiff Oncology, Inc. - Special Call TranscriptSep 23, 2020
- Cardiff Oncology Inc Onvansertib Clinical Trials TranscriptMay 18, 2020
- Trovagene Inc at Needham Healthcare Conference TranscriptApr 15, 2020
- Trovagene Inc Business Update Conference Call TranscriptJun 07, 2019
Trovagene Inc at Needham Healthcare Conference Transcript
Thank you for joining. This is Mark Erlander. I am the Chief Scientific Officer for Trovagene Oncology. And we greatly appreciate your time today and the opportunity to tell you more about our Company and what we are doing.
Go to slide 3, really Trovagene is a clinical stage oncology therapeutics company and really the highlights of our Company are as follows. First of all, we are developing a drug called onvansertib. It's a first-in-class third generation PLK1 inhibitor that's oral and well tolerated.
Today I'm going to talk to you about three different trials that are ongoing demonstrating not only tolerability -- well, safe, but also efficacy. We have a predictive biomarker program for each of our trials which is useful, obviously, for identifying which patients have the greatest likelihood to respond.
And we really -- our approach is really the definition of precision medicine. It is really the combination -- we are using our drugs in combination with standard of care in three different indications. I'm going to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)